Volume | 72,595 |
|
|||||
News | - | ||||||
Day High | 2.38 | Low High |
|||||
Day Low | 2.17 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Revelation Biosciences Inc | REVB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
2.35 | 2.17 | 2.38 | 2.21 | 2.26 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
605 | 72,595 | US$ 2.34 | US$ 169,874 | - | 1.61 - 35.40 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
17:06:07 | 2 | US$ 2.10 | USD |
Revelation Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
2.1k | 209.91k | - | 0 | -120k | -0.57 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Revelation Biosciences News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical REVB Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.17 | 2.4799 | 1.81 | 2.26 | 34,639 | 0.04 | 1.84% |
1 Month | 1.83 | 2.4799 | 1.61 | 2.05 | 43,916 | 0.38 | 20.77% |
3 Months | 2.40 | 2.96 | 1.61 | 2.24 | 49,910 | -0.19 | -7.92% |
6 Months | 16.20 | 25.26 | 1.61 | 6.93 | 266,671 | -13.99 | -86.36% |
1 Year | 33.00 | 35.40 | 1.61 | 11.07 | 175,137 | -30.79 | -93.30% |
3 Years | 8,799.00 | 10,237.50 | 1.61 | 980.14 | 1,208,508 | -8,796.79 | -99.97% |
5 Years | 8,799.00 | 10,237.50 | 1.61 | 980.14 | 1,208,508 | -8,796.79 | -99.97% |
Revelation Biosciences Description
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99. |